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Inflammatory bowel disease (IBD) is 
an inflammatory autoimmune disease 
caused by an inappropriate response of 
the immune system to commensal gut 
microbes [1]. There are two types of IBD, 
ulcerative colitis (UC) and Crohn’s dis-
ease (CD). UC affects the large bowel only, 
affecting variable lengths of the colon 
continuously from the rectum, primarily 
affecting the mucosa [Fig. 1]. CD can affect 
any part of the GI tract, and is a transmural 
disease [2]. Common symptoms of IBD are 
severe abdominal pain, defecation urgency 
and diarrhoea, which can contain blood.
Irritable bowel syndrome (IBS) is a func-
tional disorder of the digestive tract. It is 
characterized by its symptoms, with no 
physiological changes in the GI tract. IBS 
can be diarrhoea predominant (IBS-D), 
constipation predominant (IBS-C) or 
symptoms can alternate between the two 
(IBS-A). Common symptoms include 
abdominal pain and cramps, bloating and 
flatulence, and unusual bowel habit. IBS 
has, as yet, no known cause. People with 
IBS show abnormal gut motility and hyper-
sensitivity to pain in the GI tract. Stress 
and anxiety are known to cause changes 
in gut motility [3] with stress and anxiety 
being common symptoms of IBS. When 
under physical or psychological stress IBS 
patients showed increased gastro-intesti-
nal sensitivity when compared to healthy 
controls [4]. Recently it has been thought 
that there may be changes in the gut micro-
biota in patients with IBS, the evidence 
being that IBS symptoms often occur after 
infective gastroenteritis or in patients in 
remission from IBD or diverticulitis. SIBO 
(small intestinal bowel overgrowth) has 
also been implicated in IBS and other func-
tion bowel disorders. One current hypoth-
esis is that an altered microbiota activates 
the immune system within the mucosa, 
leading to an increase in epithelial perme-
ability, causing dysregulation of the enteric 
nervous system [5]. Genome-wide asso-
ciation studies have successfully identified 
many genetic loci involved in susceptibil-
ity to IBD, and it is thought that genetic 
factors may also play a role in IBS [1].
Diagnosis of GI disease
IBS-D can present with symptoms similar 
to IBD and other non-functional bowel 
conditions. The diagnosis of IBS is often 
one of exclusion, where more serious bowel 
diseases, such as IBD or colon cancer which 
present with common symptoms, are ruled 
out. The current gold standard for diagno-
sis of IBD is endoscopic and histological 
testing; however, these investigations are 
both invasive and costly, and have asso-
ciated risks. Of the patients referred for 
endoscopy few actually have organic bowel 
disease [6]. The costs associated with func-
tional bowel disease are significant, with 
healthcare costs for IBS patients being sig-
nificantly higher than non IBS controls [7].
There are currently no known biomark-
ers of IBS. There are various biomarkers 
that have potential in the differentiation 
of functional from inflammatory gastro-
intestinal disease, but there is still a need 
to identify biomarkers and to develop 
quicker, lower cost and less invasive testing 
for diagnosis of gastro-intestinal disease.
Biomarkers such as lactoferrin, calprotec-
tin, c-reactive protein (CRP) and eryth-
rocyte sedimentation rate (ECR) have all 
been used to help distinguish functional 
from inflammatory bowel disorders and to 
diagnose IBD. Serological markers such as 
antibodies to bacterial and fungal antigens 
that can indicate an abnormal response to 
commensal microbes can also be useful in 
identifying IBD.
Fecal calprotectin and lactoferrin are pro-
tein biomarkers of inflammation. In 2010 
a meta-analysis of six studies (n=670) in 
adults by Van Rheenen et al. [8] found 
that screening patients by testing fecal 
calprotectin levels would have reduced 
the number of endoscopies performed by 
67%, although its diagnosis would have 
been delayed in 6% of patients. When tak-
ing a weighted mean of 19 studies includ-
ing 1001 patients, where IBD patients were 
compared with controls of IBS and other 
colonic diseases, fecal lactoferrin has a 
sensitivity and specificity of 80% and 82%, 
respectively [9].
Although these biomarkers can be use-
ful as part of the screening process when 
establishing a diagnosis [6, 8], there is cur-
rently no biomarker or test that can replace 
the need for endoscopic and histological 
investigations. Mass spectrometry tech-
niques are at the forefront of research for 
biomarker prospecting for IBS/IBD.
Mass spectrometry
Mass spectrometry (MS) has the ability to 
identify numerous compounds in a single 
sample. It is also high throughput allowing 
rapid analysis of many samples, which is 
especially useful for large studies or for the 
diagnosis of many samples. The ability to 
obtain results quickly, usually in less than 
1 hour makes it attractive for clinical use.
Proteomic approach
Although MS (with associated sample 
vaporisation methods) was originally lim-
ited to low molecular weight volatile com-
pounds, in the last 2 decades advances in 
MS technology have enabled its use with 
high molecular weight compounds, chang-
ing the way proteins are analysed. The soft 
ionization techniques electrospray ioniza-
tion (ESI) and matrix-assisted laser des-
orption/ionization (MALDI) allow for the 
analysis of proteins and other macromol-
ecules [10]. The identification of proteins 
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through peptide mass fingerprinting, or peptide sequencing using 
MS is more rapid than techniques such as de novo protein sequenc-
ing and data can be analysed automatically. MS can also be used to 
determine the abundance of a molecule in a sample [10].
Differential protein expression can identify different diseases, 
and can indicate the degree of the disease state, or be used to 
assess the effects of treatment – for example the response of IBD 
patients to anti-TNF alpha antibodies (infliximab) [11]. It also has 
applications in the identification of protein biomarkers.
In 2011 MALDI-MS was used by M’koma et al. for tissue anal-
ysis; through profiling of the proteome of the colonic submu-
cosa they were able to distinguish UC from CD by comparing 
proteomic spectra. Definitive diagnosis of either UC or CD 
is important as people with UC also have an increased risk of 
colon cancer [12].
Goo et al. have investigated protein biomarkers for IBS. ESI with 
LC-MS was used on protein fragments from the urine of women 
with IBS. They found differences in some specific components of 
the urinary proteome, and demonstrated that there is a possibility 
for future biomarker studies for IBS [13].
There are still limitations to mass spectrometric protein analysis, 
for example the difficulty in detecting hydrophobic membrane 
proteins. However, it seems promising that, with the advances in 
mass spectrometry technology, there will be an increase in the 
discovery of protein biomarkers and key pathogenic factors of 
gastro–intestinal disease, and improved diagnosis and therapy.
Metabolomic approach
The metabolome is the set of small molecule metabolites found 
in a biological sample. Unlike proteomics, metabolomics can be a 
direct measure of production of compounds and activity of cells 
or systems in an organism. This can be especially useful when 
looking for disease biomarkers in IBS and other bowel diseases 
as it can be used to understand the environment of the GI tract, 
as well as factors such as digestion and absorption of dietary 
products and gut microbial activity [14], which are implicated in 
IBS pathogenesis.
Researchers have explored the use of various techniques incor-
porating MS on breath [15], urine [16] and stool [17] samples in 
search of metabolic biomarkers of bowel disease for non-invasive 
testing and many possible candidates have been identified.
The commonly used analytical techniques in metabolomics are 
GC-MS (gas chromatography-mass spectrometry) or LC-MS (liq-
uid chromatography-mass spectrometry) and NMR (nuclear mag-
netic resonance) spectrometry. NMR has the advantage that there 
is no need to have the compounds in the vapour phase, although 
the limit of detection using NMR is much poorer than MS.
LC-MS metabolomic studies have been recently undertaken 
using urine to identify putative colon inflammation biomarkers 
[18]. The authors note that urinary biomarkers would be pref-
erable to sampling intestinal tissue or blood as the collection of 
urine samples is non-invasive and multiple samples are more 
readily obtained.
The analysis of volatile organic compounds (VOCs) or metabo-
lites (VOMs) is an emerging area of disease diagnosis. VOCs are 
small molecules that are readily analysed by GC-MS. Other com-
monly used methods of VOC detection are selected ion flow tube 
mass spectrometry (SIFT-MS) [Fig. 2], and the similar technique 
of PTR-MS (proton transfer MS).
There are already several FDA approved tests using volatiles from 
breath. These include testing for heart transplant rejection, hemo-
globin breakdown in children and measurement of hydrogen or 
methane to diagnose GI lactose or fructose malabsorption. The 
measurement of breath hydrogen has also been used to diagnose 
SIBO. Recent work by Španĕl et al. using SIFT-MS quantified the 
breath pentane concentration of study subjects using the reac-
tion of O2+ with pentane. It was found that patients with CD and 
UC had significantly elevated breath pentane levels compared to 
healthy controls [15].
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Figure 1. Diagram of the gut showing the areas where inflammatory 
disease is most likely to occur.
Testing for fecal biomarkers of bowel dis-
ease is facile as samples are easily obtained 
and have been in contact with the gastro 
intestinal tract. The changes in the odour 
of feces and flatus reported in many bowel 
conditions are due to changes in the VOC 
profile. This altered VOC profile could lead 
to identification of biomarkers of disease 
state. A recent pilot study carried out by 
Ahmed et al. using GC-MS on fecal sam-
ples from IBD and IBS patients identified a 
key set of VOMs which were able to distin-
guish IBS-D from Active IBD with a sensi-
tivity of 96% and a specificity of 80% [19].
Conclusions
MS techniques show promise for the iden-
tification of biomarkers of various GI dis-
ease states, which have the potential to 
reduce invasive testing, improve patient 
care and reduce healthcare costs.
Instrumentation is still expensive and 
relatively large, limiting its use in hospital 
settings and particularly limiting its use 
for near-patient testing. Also biomarker 
discovery is still in its infancy and much 
remains to be clarified in relation to the 
significance of markers to disease and the 
underlying metabolic pathways.
However, work to reduce the size and cost 
of mass spectrometers is well advanced 
and would open up the possibility of 
instruments being deployed for point-of-
care detection and monitoring of diseases 
including IBS and IBD.
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The terminology of mass spectrometry
GC-MS: Gas chromatography-mass spectrometry This is the gold standard method for pros-
pecting for volatile biomarkers. The first part, GC, separates the volatile compounds using a 
flow of gas (mobile phase) through a long coated silica column. The coating (stationary phase) 
retains different volatiles according to their boiling point or polarity etc. The second part, the 
mass spectral detector, fragments the separated molecules into positive ions and their mass to 
charge ratio is identified. They are then matched to an extensive library of mass spectral frag-
mentations to aid structural identification.  
LC-MS: Liquid chromatography-mass spectrometry This is similar to GC-MS except that a 
solvent rather than gas is used as the mobile phase
SIFT-MS: Selective ion flow transfer-mass spectrometry This method permits real time anal-
yses of known volatile compounds and can be used readily to analyse the headspace of breath, 
urine and stool. Unlike the GC- or LC-MS there is no chromatography step so is extremely fast 
and gives quantitative analyses. The reaction of the analyte with precursor ions (H3O+, NO+, 
O2+) forms product ions. Detection of the precursor and product ions of interest is used to 
quantify the absolute concentration of a particular VOC in the sample using the known reac-
tion kinetics.
PTR-MS: Proton transfer reaction mass spectrometry A PTR-MS instrument consists 
of an ion source directly connected to a drift tube (in contrast to SIFT-MS no mass filter is 
interconnected) and an analyzing system (quadrupole mass analyser or time-of-flight mass 
spectrometer).
ESI: Electrospray ionization Liquid solvent containing the analyte is aerosolised by electro-
spray, a high voltage is applied to the liquid causing it to aerosolise into charged droplets. As the 
solvent evaporation occurs, the droplet shrinks until it reaches the point that the surface tension 
can no longer sustain the charge (the Rayleigh limit) at which point a ‘Coulombic explosion’ 
occurs and the droplet is ripped apart. This produces smaller droplets. The process is repeated 
with the smaller droplets until ‘naked’ charged analyte molecules are formed. This process is 
useful for molecules such as proteins as it is a fairly gentle method if ionisation which doesn’t 
disrupt the non-covalent bonds in the molecule.  
MALDI: Matrix assisted laser desorption The analyte is embedded in a matrix, a laser beam 
is then focussed on the matrix which absorbs light of the frequency of the laser, this causes 
excitation of the molecules and desorption of matrix-analyte ions from the matrix. The matrix 
molecules then evaporate away leaving free analyte ions.
Peptide mass fingerprinting  Proteins are digested into their constituent peptide fragments 
(the protein fingerprint), the proteins are then identified by matching the mass obtained for the 
fragments to the mass of known fragments using a database.
Figure 2. Photo of a SIFT mass spectrometer 
analysing VOCs in the breath of a volunteer in 
real time. Reproduced with kind permission of 
Patrik Španel.
